Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New research delivered at AAIC

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, welcomes a number of new scientific posters (available for review by following the links below) presented this week at the Alzheimer's Association International Conference ('AAIC') in Washington, D.C.

Collectively the scientific posters highlight the sensitivity and effectiveness of the Company's latest healthcare technology innovations and clinical trial assessment systems including the new Cantab Connect Prodromal Alzheimer's product. This cloud-based clinical trials product aids the development of effective treatments and interventions for prodromal Alzheimer's, the earliest stage of dementia.

The Company presented the latest data from global studies using iPad-based Cantab technology for cognitive testing in clinical trials. One study illustrates the use of Cantab to detect and measure amnestic mild cognitive impairment (MCI)1, a slight but noticeable decline in cognitive abilities, including memory. The initial clinical diagnosis of MCI can be unstable, with the degree of cognitive impairment rapidly worsening in some people. This research used Cantab technology to predict stable versus transient MCI in patients over a short period of time to demonstrate the sensitivity and specificity of the tests to this early stage of the disease.

A second scientific poster draws analyses from a large epidemiologic study of 2,110 individuals aged 56-86 and provides important information on the expected patterns of cognitive performance in a general population sample in mid to late life. Such information can be beneficial to drug development companies for identifying positive effects of new treatments for Alzheimer's disease in clinical trials2.

AAIC is being held in Washington, D.C, US from 18 - 23 July 2015 and is the largest gathering for the dementia research community bringing together clinicians, care providers and companies to share their latest research, theories and results. Over the week, Cambridge Cognition will present data from seven studies using their proprietary Cantab technology to sensitively measure cognitive performance in Alzheimer's disease.

Dr Kenton Zavitz, Director of Clinical Affairs for Cambridge Cognition, said: "The last ten years have seen growth in research of early detection in Alzheimer's, which is key to slowing and possibly halting the disease. With the new Cantab Connect Prodromal Alzheimer's product launched at AAIC this week, the pharmaceutical industry now has a validated, sensitive and consistent measure of Alzheimer's drug efficacy throughout the disease course. When a disease-modifying treatment does finally come to market, we expect that Cantab Connect will play a role in its discovery."

Steven Powell, Chief Operating Officer, said: "We are pleased to present this research at the largest global forum for the dementia research community. These publications provide the Company with an opportunity to showcase its expertise in dementia assessment and meet with thought leaders, clinicians and care providers to share the extensive research produced using the Company's products."

Enquiries:

References to the scientific posters:

1. Link to the PDF file of technical poster:

'Stability of amnestic MCI: Cantab paired associate learning as a predictor of a consistent diagnosis.'

http://www.cambridgecognition.com/blog/entry/stability-of-amnestic-mci-cantab-pal-predictor-consistent-diagnosis 

2. Link to the PDF file of technical poster:

'Cross sectional normative CANTAB data in an epidemiological sample of elderly subjects: Data from the Heniz Nixdorf Recall Study.'

http://www.cambridgecognition.com/blog/entry/cross-sectional-normative-cantab-data-epidemiological-sample-elderly

For more on Cambridge Cognition at AAIC 2015 visit: www.cambridgecognition.com/aaic2015 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.